Swiss pharmaceutical supplier Skan Group reported a significant increase in both revenue and profit for the period, supported by a lower volume of project postponements.
The Basel-based company noted that operational stability improved as fewer clients delayed ongoing initiatives, driving demand for its isolator systems and cleanroom equipment. Following the financial update, shares in Skan experienced strong demand on the market.
